<DOC>
	<DOCNO>NCT02345707</DOCNO>
	<brief_summary>This study single-center , randomize , open-label , two cohort , 3-way cross-over design 36 subject assess oral bioavailability four new cabotegravir ( CAB ) sodium salt tablet formulation relative current CAB sodium salt formulation use phase IIb study fast condition . All treatment administer single 30 mg dos CAB . Safety evaluations serial PK sample collect treatment period . A follow-up visit occur 10 - 14 day last dose study drug . Treatment period dos separate 14 day washout . Participation study approximately 12 week .</brief_summary>
	<brief_title>Relative Bioavailability Study Phase III Tablet Formulation Cabotegravir</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Males females 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 18.5 31.0 kg/ meter square ( m^2 ) ( inclusive ) . Male Female Female subject eligible participate pregnant ( confirm negative serum human chorionic gonadotrophin ( hCG ) test ) , lactate , least one follow condition applies : ) Nonreproductive potential define : Premenopausal females one follow [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy . b ) Postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause &gt; 40 milliInternational Units ( MIU ) / milliliter ( mL ) estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 147 picomole [ pmol ] / liter [ L ] ) confirmatory ] . c ) Reproductive potential agrees follow one option list GlaxoSmithKline ( GSK ) Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) requirement 30 day prior first dose study medication last dose study medication completion followup visit . GSK Modified List Highly Effective Methods Avoiding Pregnancy FRP follow . This list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis . ) Intrauterine device intrauterine system meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label . b ) Male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject . c ) Male condom combine vaginal spermicide ( foam , gel , film , cream , suppository ) follow 3 situation low risk developmental toxicity : Vaccines ; Monoclonal antibody target biology concern ; Compounds complete reproductive toxicology package show signal developmental toxicity . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Sexual inactivity abstinence must consistent preferred usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History clinically significant cardiovascular disease include : ) Exclusion criterion screen Electrocardiogram ( ECG ) ( single repeat allow eligibility determination ) Heart rate : Males : &lt; 45 &gt; 100 beat per minute , Females : &lt; 50 &gt; 100 beat per minute ; QRS duration : &gt; 120 millisecond ( msec ) , QTc interval ( B ) : &gt; 450 msec ; b ) Evidence previous myocardial infarction ( pathologic Q wave , ST segment change ( except early repolarization ) . c ) History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . ) Any conduction abnormality ( include specific leave right complete bundle branch block , atrioventricular block ( AV ) block [ 2nd degree ( type II ) high ] , Wolf Parkinson White [ WPW ] syndrome ) . e ) Sinus pause &gt; 3 second . f ) Any significant arrhythmia , opinion principal Investigator GSK Medical Monitor , interfere safety individual subject . g ) Nonsustained ( &gt; =3 consecutive ventricular ectopic beat ) sustain ventricular tachycardia . NOTES : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use specify Reporting Analysis Plan ( RAP ) . Concomitant medication prohibit study . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . Hepatitis B core antibody ( HBcAb ) negative hepatitis b surface antibody also exclude . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject 's systolic blood pressure outside range 90140 millimeter mercury ( mmHg ) , diastolic blood pressure outside range 4590 mmHg . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cabotegravir</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>